Related Experiment Video
Updated: Jun 14, 2025

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans
Published on: October 5, 2020
CircRAPGEF5 acts as a modulator of RAS/RAF/MEK/ERK signaling during colorectal carcinogenesis
Zhipeng Yin1, Hao Li2, Heng Zhao2
1Department of Gastrointestinal Surgery, The People's Hospital of Bozhou, The Affiliated Bozhou Hospital of Anhui Medical University, Bozhou, China.
Abstract:
Mutations in oncogenes such as KRAS, NRAS and BRAF promote the growth and survival of tumors, while excessive RAS/RAF/MEK/ERK activation inhibits tumor growth. In this study we examined the precise regulatory machinery that maintains a moderate RAS/RAF/MEK/ERK pathway activation during CRC. Here, using bioinformatic analysis, transcriptomic profiling, gene silencing and cellular assays we discovered that a circular RNA, circRAPGEF5, is significantly upregulated in KRAS mutant colorectal cancer (CRC) cells. CircRAPGEF5 suppressed mutant and constitutively activated KRAS and the expression of the death receptor TNFRSF10A. Silencing of circRAPGEF5-induced RAS/RAF/MEK/ERK signaling hyperactivation and apoptosis in CRC cells suggesting that an upregulation of circRAPEF5 may suppress the expression of TNFRSF10A and aid CRC progression by preventing apoptosis, while the direct interactions between circRAPGEF5 and elements of the RAS/RAF/MEK/ERK pathway was not identified, which nevertheless can be the basis for future research. Moreover, EIF4A3, was observed to share a similar expression pattern with circRAPEF5 and demonstrated to be a major controller of circRAPGEF5 via the promotion of circRAPGEF5 circularization and its silencing reduced circRAPGEF5 levels. Taken together, our findings reveal a mechanism of accurate RAS/RAF/MEK/ERK signaling regulation during CRC progression maintained by upregulation of circRAPGEF5 which may be a plausible target for future clinical applications that seek to induce CRC cell apoptosis via the RAS/RAF/MEK/ERK signaling pathway.
Insights
A circular RNA, circRAPGEF5, is upregulated in KRAS mutant colorectal cancer (CRC), suppressing tumor growth by maintaining moderate RAS/RAF/MEK/ERK pathway activation and preventing apoptosis. This pathway regulation offers potential therapeutic targets for CRC.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Mutations in oncogenes like KRAS, NRAS, and BRAF drive tumor growth.
- Paradoxically, excessive RAS/RAF/MEK/ERK pathway activation can inhibit tumor progression.
- Understanding the regulation of this pathway in colorectal cancer (CRC) is crucial.
Purpose of the Study:
- To investigate the regulatory mechanisms maintaining moderate RAS/RAF/MEK/ERK pathway activation in CRC.
- To identify novel molecular players involved in RAS/RAF/MEK/ERK pathway regulation during colorectal cancer progression.
Main Methods:
- Bioinformatic analysis
- Transcriptomic profiling
- Gene silencing experiments
- Cellular assays
Main Results:
- A circular RNA, circRAPGEF5, was significantly upregulated in KRAS-mutant CRC cells.
- CircRAPGEF5 suppressed mutant KRAS and TNFRSF10A expression, preventing apoptosis.
- Silencing circRAPGEF5 led to RAS/RAF/MEK/ERK pathway hyperactivation and apoptosis in CRC cells.
- EIF4A3 was identified as a key regulator promoting circRAPGEF5 circularization.
Conclusions:
- Upregulation of circRAPGEF5 maintains moderate RAS/RAF/MEK/ERK signaling, suppressing apoptosis and aiding CRC progression.
- CircRAPGEF5 represents a potential therapeutic target for inducing CRC cell apoptosis via the RAS/RAF/MEK/ERK pathway.
- EIF4A3 controls circRAPGEF5 levels, highlighting a novel regulatory axis.
More Related Videos
07:49Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
Published on: July 17, 2019
06:44Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells
Published on: March 1, 2024
Related Concept Videos
The Ras Gene
Ras is a...
MAPK Signaling Cascades
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
Mitogens and the Cell Cycle